Loading…
As of 9 Nov 2026: SHUKRAPHAR ₹82.05 (m-cap ₹3,618 Cr, P/E 110.9) vs Zota Health Care ₹1,273.60 (m-cap ₹4,410 Cr). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | SHUKRAPHAR | Zota Health Care |
|---|---|---|
| Share price | ₹82.05 | ₹1,273.60 |
| Day change | +0.58% | +2.70% |
| Market cap | ₹3,618 Cr | ₹4,410 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 110.9 | — |
| P/BPrice ÷ book value per share. | 40.2 | 6.4 |
| ROEReturn on equity. | 28.9% | -15.1% |
| ROCEReturn on capital employed. | 36.9% | -8.0% |
| Sales growth (3Y CAGR) | — | — |
| Profit growth (3Y CAGR) | — | — |
| Debt to equity | 0.06 | 0.39 |
| Dividend yield | 0.01% | 0.08% |
| 1-year price return | — | −17.0% |
| Promoter holding | 51.2% | — |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Zota Health Care Ltd is larger, with a market cap of ₹4,410 Cr against ₹3,618 Cr for Shukra Pharmaceuticals Ltd as of 9 Nov 2026 — about 1.2 times the size.
Zota Health Care Ltd has no meaningful P/E right now (a loss over the last twelve months, or no reported earnings), so the two cannot be compared on P/E.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours (delayed by up to 15 minutes) and ratios update when the companies report results. Each number is the same one shown on the two stock pages.